|
India Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The India Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for India .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Indian pharmaceutical and healthcare industry.
Competitive intelligence, Indian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Indian market.
The India Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s India Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Indian pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on India to test other views – a key input for successful budgeting and strategic business planning in the Indian pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Indian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in India .
- Exploit The Latest Competitive Indian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in India .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
India Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| SWOT Analysis |
| India Pharmaceutical Industry SWOT |
| India Political SWOT |
| India Economic SWOT |
| India Business Environment SWOT |
Chapter - India's Pharmaceutical Business Environment Ratings |
| Table: Asia Pacific Pharmaceutical Business Environment Rankings For Q209 |
| Limits of Potential Returns |
| Risks to Realisation of Returns |
Chapter - India – Market Summary |
| Regulatory Environment |
| Table: Responsibilities Of India's Department Of Pharmaceuticals |
| Pharmaceutical Advertising |
| Pharmacovigilance |
| Recent Regulatory Developments |
| IP Regime |
| Table: History Of The Indian Patent System |
| Patent Disputes |
| Counterfeit Medicines |
| Table: Anti-Counterfeiting Guidelines From The Organisation Of Pharmaceutical Producers Of India (OPPI) |
| Pricing And Reimbursement |
| Recent Pricing and Reimbursement Developments |
Chapter - Industry Trends and Developments |
| Epidemiology |
| Healthcare Sector |
| Healthcare Funding |
| Healthcare Insurance |
| Table: Health Insurance In India – Key Facts |
| Company Developments |
| Retail Pharmacy Sector |
| Table: Major Players In India's Retail Pharmacy Sector |
| Recent Pharmaceutical Retail Developments |
| Foreign Co-Operation |
| Clinical Trials |
| Recent Developments in the Clinical Trials Industry |
| Active Pharmaceutical Ingredients |
| Biotechnology Sector |
| Traditional Medicines |
| Medical Devices |
| Regulation of Medical Devices |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: India – Drug Expenditure Indicators, 2003-2013 |
| Key Growth Factors – Industry |
| Table: India – Health Expenditure Indicators, 2003-2013 (INRmn unless otherwise stated) |
| Key Growth Factors – Macroeconomic |
| Table: India - Economic Activity, 2005-2013 |
| The Global Finanical Crisis and India's Pharmaceutical Industry |
| Prescription Drug Market Forecast |
| Table: India – Prescription Market Indicators, 2004-2013 (INRmn unless otherwise stated) |
| Patented Product Market Forecast |
| Table: India – Patented Market Indicators, 2004-2013 |
| Generic Drug Market Forecast |
| Table: India – Generics Market Indicators, 2004-2013 |
| OTC Medicine Market Forecast |
| Table: India – OTC Market Indicators, 2004-2013 (US$mn unless otherwise stated) |
| Pharmaceutical Trade Forecast |
| Table: India – Pharmaceutical Trade, 2004-2013 (US$mn) |
| Medical Device Market Forecast |
| Table: India's Medical Device Market, 2003-2013 (US$bn unless otherwise stated) |
| Other Healthcare Data Forecasts |
| Table: India – Healthcare Data Indicators, 2004-2013 |
| Key Risks to BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Company Profiles |
| Leading Multinational Manufacturers |
| Pfizer |
| GlaxoSmithKline (GSK) |
| Novartis |
| Sanofi-Aventis |
| Merck & Co |
| Eli Lilly |
| Leading Indigenous Manufacturers |
| Ranbaxy Laboratories |
| Cipla |
| Dr Reddy's Laboratories |
| Aurobindo Pharmaceutical |
| Venus Remedies |
| Granules India |
| Nicholas Piramal India |
| Zydus Cadila |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
India Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
India’s pharmaceutical market is the third largest in Asia Pacific, behind China and Japan. Combined sales of prescription products and over-the-counter (OTC) medicines reached US$14.23bn in 2008 – a 12.0% increase compared to the previous year. Drug spending accounts for 1.22% of GDP and annual per capita expenditure is US$11.96. Through to 2013, BMI is forecasting a compound annual growth rate (CAGR) of 5.79% for the overall pharmaceutical market.
As of April 2009, local firm Wockhardt was in crisis. Its managing director had stepped down, the company was struggling to meet its debt obligations and a fire sale of assets was imminent. Market commentators speculated that the root cause was substantial mark-to-market losses on forex derivative bets. This swelled the company’s debt burden to INR3,000 crore (US$746mn) by the end of 2008. Considering that Wockhardt’s market capitalisation is just INR936 crore (US$185mn), creditors are rightly nervous. Investors are also increasingly bearish.
In March 2009, the Drug Technical Advisory Board recommended a ban on the use of the anti-obesity drug rimonabant due to it inducing suicidal tendencies. Manufacturers were reluctant to accept the ruling as the drug is a significant revenue stream in a country where the vast population is increasingly overweight. The final decision will be made by the Drug Controller General, and we expect removal of the cannabinoid antagonist from the market.
BMI believes India’s pharmaceutical industry will ultimately benefit from the global economic downturn. Developed countries are increasingly looking to control healthcare costs and buying cheap drugs from the sub-continent is one way to achieve this. However, in the short term, India’s contract manufacturers are likely to suffer from reduced demand for their products.
A patent application for Copaxone (glatiramer acetate), a multiple sclerosis drug marketed worldwide by Israel-based Teva Pharmaceuticals Industries, in India was blocked by India’s Natco Pharma in March 2009. The Indian patent office refused the application, which was submitted to it by Yeda Research & Development, due to obviousness and lack of inventiveness.
|
India Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |